Vishnu S. Potluri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vishnu S. Potluri has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Peter Philip Reese
Vanderbilt Center for Transplant Science, Vanderbilt University Medical Center, Nashville, Tennessee, USA
15 shared publications Peter P. Reese
Vanderbilt Center for Transplant Science, Vanderbilt University Medical Center, Nashville, Tennessee
7 shared publicationsPeter L. Abt
Department of Surgery, Perelman School of Medicine, Philadelphia, PA
5 shared publicationsEmily A. Blumberg
Division of Infectious Disease, Department of Medicine, University of Pennsylvania, Philadelphia, PA
4 shared publications- Roy D. Bloom
Renal-Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA
4 shared publications Chethan M. Puttarajappa
Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia
3 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-10
Experiential Knowledge in Multi-Agent Virtual Health Systems: The Value of an Expert Patient Agent
Multi-agent virtual systems offer new opportunities to support nuanced, human-centered health interactions by combining diverse perspectives and tailoring responses to individual needs. We investigate how incorporating experiential knowledge can address informational and emotional needs, particularly for sensitive health concerns. We introduce an Expert Patient agent capable of sharing lived experiences and peer-based perspectives to complement a Clinician agent’s medical expertise. We conducted a between-participants study with 69 Chronic Kidney Disease (CKD) patients comparing Control, MultiSet and MultiChoose conditions. We ground our study in CKD, where patients navigate complex challenges, including dietary restrictions, changes in physical appearance that affect body image, and anxiety about the possibility that they may require burdensome treatments such as dialysis in the future. Traditional clinical interactions, such as appointments with their nephrologist, can often fall short in addressing these multidimensional needs. We look into the value of integrating experiential knowledge into such systems, and whether expert patient perspectives can enhance emotional validation, relatability, and practical coping support. Results indicate that enabling user choice in a multi-agent system (MultiChoose) increases intent to seek peer support, while the single-agent system (Control) improved body image–related intentions.
- 6 September 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-10
Open AccessExperiential Knowledge in Multi-Agent Virtual Health Systems: The Value of an Expert Patient Agent
Multi-agent virtual systems offer new opportunities to support nuanced, human-centered health interactions by combining diverse perspectives and tailoring responses to individual needs. We investigate how incorporating experiential knowledge can address informational and emotional needs, particularly for sensitive health concerns. We introduce an Expert Patient agent capable of sharing lived experiences and peer-based perspectives to complement a Clinician agent’s medical expertise. We conducted a between-participants study with 69 Chronic Kidney Disease (CKD) patients comparing Control, MultiSet and MultiChoose conditions. We ground our study in CKD, where patients navigate complex challenges, including dietary restrictions, changes in physical appearance that affect body image, and anxiety about the possibility that they may require burdensome treatments such as dialysis in the future. Traditional clinical interactions, such as appointments with their nephrologist, can often fall short in addressing these multidimensional needs. We look into the value of integrating experiential knowledge into such systems, and whether expert patient perspectives can enhance emotional validation, relatability, and practical coping support. Results indicate that enabling user choice in a multi-agent system (MultiChoose) increases intent to seek peer support, while the single-agent system (Control) improved body image–related intentions.
- Open Access
- 24 August 2026
- Published by Wolters Kluwer Health in Kidney360
Underutilization of Preemptive Waitlisting for Prior Living Donors Who Develop ESKD
Was not provided for this article.
- 24 August 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessUnderutilization of Preemptive Waitlisting for Prior Living Donors Who Develop ESKD
Was not provided for this article.
- Open Access
- 14 July 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (4) , 573-580.e1
An Interactive Virtual Nephrologist to Engage Patients With Advanced CKD About Transplantation
- 14 July 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (4) , 573-580.e1
Open AccessAn Interactive Virtual Nephrologist to Engage Patients With Advanced CKD About Transplantation
- Open Access
- 22 April 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (5) , e1940
Outcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria—A Single-center Experience
Background.: The impact of revised Organ Procurement and Transplantation Network policy defining eligibility for simultaneous liver-kidney (SLK) and the safety net criteria for kidney after liver (KAL) transplantation remains insufficiently characterized. Methods.: We conducted a retrospective study of adults (>18 y) evaluated for liver transplant alone (LTA), SLK, or KAL at the University of Pennsylvania from August 10, 2017, to February 28, 2023. The primary outcome was mortality among SLK and KAL recipients and those patients waitlisted for KAL. Secondary outcomes included native kidney recovery in LTA recipients, estimated glomerular filtration rate (eGFR) at 1 y post-kidney transplant, and time between liver and kidney transplants. Results.: Of 1655 patients evaluated, 57 (3.4%) met SLK criteria; 49 (86%) underwent SLK and 8 (14%) received LTA. Among 1598 LTA candidates, 1010 (63%) were waitlisted and 717 (71%) received LTA. After excluding 9 early deaths (1.3%) that were unrelated to KAL delay, 67 survivors (9.5%) met KAL safety net criteria. Thirty-four (50.8%) were waitlisted (15 transplanted over a median of 220 d), 30 (44.8%) declined, and 3 (4.8%) remained under evaluation. Mortality was 4.1% after SLK and no deaths occurred after KAL >3.7 and 3.1 y of follow-up, with 3 deaths (8.8%) among KAL waitlisted patients. Of the 16 KAL waitlisted patients alive without kidney transplant at last follow-up, 2 (12.5%) were delisted after documented renal recovery and an additional 9 (56.3%) had eGFR >20 ml/min/1.73 m 2 and were being considered for delisting; together, 11 (68.8%) met predefined criteria for substantial native kidney recovery. One-year median eGFR was similar (SLK 51 versus KAL 54 mL/min/1.73 m 2 ; P = 0.6). Conclusions.: Early post-LTA mortality was unrelated to delayed KAL transplantation. Recovery of native kidney function while waiting for KAL was frequent. KAL transplants occurred within a year of LTA with favorable survival and graft outcomes.
- 22 April 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (5) , e1940
Open AccessOutcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria—A Single-center Experience
Background.: The impact of revised Organ Procurement and Transplantation Network policy defining eligibility for simultaneous liver-kidney (SLK) and the safety net criteria for kidney after liver (KAL) transplantation remains insufficiently characterized. Methods.: We conducted a retrospective study of adults (>18 y) evaluated for liver transplant alone (LTA), SLK, or KAL at the University of Pennsylvania from August 10, 2017, to February 28, 2023. The primary outcome was mortality among SLK and KAL recipients and those patients waitlisted for KAL. Secondary outcomes included native kidney recovery in LTA recipients, estimated glomerular filtration rate (eGFR) at 1 y post-kidney transplant, and time between liver and kidney transplants. Results.: Of 1655 patients evaluated, 57 (3.4%) met SLK criteria; 49 (86%) underwent SLK and 8 (14%) received LTA. Among 1598 LTA candidates, 1010 (63%) were waitlisted and 717 (71%) received LTA. After excluding 9 early deaths (1.3%) that were unrelated to KAL delay, 67 survivors (9.5%) met KAL safety net criteria. Thirty-four (50.8%) were waitlisted (15 transplanted over a median of 220 d), 30 (44.8%) declined, and 3 (4.8%) remained under evaluation. Mortality was 4.1% after SLK and no deaths occurred after KAL >3.7 and 3.1 y of follow-up, with 3 deaths (8.8%) among KAL waitlisted patients. Of the 16 KAL waitlisted patients alive without kidney transplant at last follow-up, 2 (12.5%) were delisted after documented renal recovery and an additional 9 (56.3%) had eGFR >20 ml/min/1.73 m 2 and were being considered for delisting; together, 11 (68.8%) met predefined criteria for substantial native kidney recovery. One-year median eGFR was similar (SLK 51 versus KAL 54 mL/min/1.73 m 2 ; P = 0.6). Conclusions.: Early post-LTA mortality was unrelated to delayed KAL transplantation. Recovery of native kidney function while waiting for KAL was frequent. KAL transplants occurred within a year of LTA with favorable survival and graft outcomes.
- Open Access
- 21 April 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (2) , 206-216.e1
Allocation of Kidney Allografts From Donors With Kidney Donor Profile Index <35% and the Impact of Kidney Donor Profile Index Revisions on Access to Transplantation for Children
- 21 April 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (2) , 206-216.e1
Open AccessAllocation of Kidney Allografts From Donors With Kidney Donor Profile Index <35% and the Impact of Kidney Donor Profile Index Revisions on Access to Transplantation for Children
- 28 October 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (16) , 1482-1484
Donor-Derived Epstein-Barr Virus Infection Among Pediatric Kidney Transplant Recipients
This study uses US national data to examine Epstein-Barr virus–seronegative donor kidney use among Epstein-Barr virus–seronegative children.
- 28 October 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (16) , 1482-1484
Donor-Derived Epstein-Barr Virus Infection Among Pediatric Kidney Transplant Recipients
This study uses US national data to examine Epstein-Barr virus–seronegative donor kidney use among Epstein-Barr virus–seronegative children.
- Open Access
- 22 October 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (1) , 18-30
Assessing Deceased-Donor Kidneys Through Posttransplant Survival Prediction Algorithms
- 22 October 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (1) , 18-30
Open AccessAssessing Deceased-Donor Kidneys Through Posttransplant Survival Prediction Algorithms
- Open Access
- 7 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (10) , e70333
Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients
Background: BK viremia is associated with worse kidney transplant function and de novo donor‐specific antibodies (DSA), but mortality and graft survival are not impacted in the short‐ and intermediate‐term. The long‐term impact of BK viremia remains unclear. Methods: We performed a single‐center retrospective study on 1058 consecutive kidney or kidney‐pancreas transplant recipients. We classified the cohort based on the presence or absence of BK viremia, BK viral loads, persistence of BK viremia, and pre‐existing or de novo DSA. Outcomes included mortality, graft loss, death‐censored graft survival (DCGS), estimated glomerular filtration rate, biopsy‐proven acute rejection (BPAR), de novo DSA, ureteral stenosis, and genitourinary (GU) malignancies. Results: Over a median follow‐up period of 9.7 years, there was no difference in graft loss ( p = 0.08) and mortality ( p = 0.56). Time‐varying multivariable analysis showed no difference in DCGS [HR 1.02, (0.91–1.16)]. Compared to never BK viremic patients, patients with BK viremia had similar graft function at 5 and 10 years ( p = 0.09 and 0.65, respectively), rates of GU malignancies (7.0% vs. 5.2%, p = 0.35) and ureteral stenosis (0.8% vs. 0.4%, p = 0.63). Patients with BK viral loads >10 000 copies/mL had a higher risk of de novo DSA [HR 1.71, (1.08–2.68)] and BPAR [HR 2.11, (1.28–3.47)]. Conclusions: BK viremia did not impact mortality, graft loss, kidney function, GU malignancies, and ureteral stenosis over long‐term follow‐up, but BPAR episodes and development of de novo DSA were higher with viral loads >10 000 copies/mL. Strict monitoring protocols and immunosuppression reduction strategies are effective in minimizing the risk associated with BK viremia.
- 7 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (10) , e70333
Open AccessLong‐Term Outcomes of BK Viremia in Kidney Transplant Recipients
Background: BK viremia is associated with worse kidney transplant function and de novo donor‐specific antibodies (DSA), but mortality and graft survival are not impacted in the short‐ and intermediate‐term. The long‐term impact of BK viremia remains unclear. Methods: We performed a single‐center retrospective study on 1058 consecutive kidney or kidney‐pancreas transplant recipients. We classified the cohort based on the presence or absence of BK viremia, BK viral loads, persistence of BK viremia, and pre‐existing or de novo DSA. Outcomes included mortality, graft loss, death‐censored graft survival (DCGS), estimated glomerular filtration rate, biopsy‐proven acute rejection (BPAR), de novo DSA, ureteral stenosis, and genitourinary (GU) malignancies. Results: Over a median follow‐up period of 9.7 years, there was no difference in graft loss ( p = 0.08) and mortality ( p = 0.56). Time‐varying multivariable analysis showed no difference in DCGS [HR 1.02, (0.91–1.16)]. Compared to never BK viremic patients, patients with BK viremia had similar graft function at 5 and 10 years ( p = 0.09 and 0.65, respectively), rates of GU malignancies (7.0% vs. 5.2%, p = 0.35) and ureteral stenosis (0.8% vs. 0.4%, p = 0.63). Patients with BK viral loads >10 000 copies/mL had a higher risk of de novo DSA [HR 1.71, (1.08–2.68)] and BPAR [HR 2.11, (1.28–3.47)]. Conclusions: BK viremia did not impact mortality, graft loss, kidney function, GU malignancies, and ureteral stenosis over long‐term follow‐up, but BPAR episodes and development of de novo DSA were higher with viral loads >10 000 copies/mL. Strict monitoring protocols and immunosuppression reduction strategies are effective in minimizing the risk associated with BK viremia.
- 11 September 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70167
Consent to Receive Offers for Kidneys From Donors With Hepatitis C Among Pediatric Kidney Transplant Candidates in the United States
Background: Changes to the calculation of the Kidney Donor Profile Index (KDPI) have lowered the KDPI of hepatitis C (HCV+) donor kidneys; therefore, increasing the proportion of pediatric‐prioritized kidneys that are HCV+. We aimed to study consent rates for HCV+ kidneys among pediatric kidney transplant candidates. Methods: We identified pediatric candidates waitlisted from 2019 to 2024 and excluded those who received a living donor transplant. We used logistic regression to identify candidate characteristics associated with HCV+ offer consent and Cox proportional hazards models to determine the association between HCV+ offer consent and the rate of deceased donor transplantation. Results: Among 3202 candidates included in the analysis, 124 (4%) consented to receive HCV+ deceased donor kidney offers, and 3077 (96%) did not. In adjusted logistic regression, higher candidate age (OR 1.09 per year, 95% CI 1.03–1.15, p = 0.002) and high PRA status (OR 2.76, 95% CI 1.42–5.37, p = 0.003) were associated with a higher odds of consenting to receive HCV+ donor offers, whereas Hispanic ethnicity was associated with lower odds (OR 0.44, 95% CI 0.28–0.72, p = 0.001) of consenting to receive these offers. 2773 candidates (87%) received a transplant. There was no significant association between HCV+ donor offer consent status and transplant rate after adjusting for candidate characteristics. Only 1 received a kidney from a HCV+ donor. Conclusions: Consent to receive HCV+ donor kidney offers was rare among pediatric kidney transplant candidates. Allocation changes that increase the proportion of pediatric‐prioritized kidneys that are HCV+ may decrease access to transplant for pediatric candidates.
- 11 September 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70167
Consent to Receive Offers for Kidneys From Donors With Hepatitis C Among Pediatric Kidney Transplant Candidates in the United States
Background: Changes to the calculation of the Kidney Donor Profile Index (KDPI) have lowered the KDPI of hepatitis C (HCV+) donor kidneys; therefore, increasing the proportion of pediatric‐prioritized kidneys that are HCV+. We aimed to study consent rates for HCV+ kidneys among pediatric kidney transplant candidates. Methods: We identified pediatric candidates waitlisted from 2019 to 2024 and excluded those who received a living donor transplant. We used logistic regression to identify candidate characteristics associated with HCV+ offer consent and Cox proportional hazards models to determine the association between HCV+ offer consent and the rate of deceased donor transplantation. Results: Among 3202 candidates included in the analysis, 124 (4%) consented to receive HCV+ deceased donor kidney offers, and 3077 (96%) did not. In adjusted logistic regression, higher candidate age (OR 1.09 per year, 95% CI 1.03–1.15, p = 0.002) and high PRA status (OR 2.76, 95% CI 1.42–5.37, p = 0.003) were associated with a higher odds of consenting to receive HCV+ donor offers, whereas Hispanic ethnicity was associated with lower odds (OR 0.44, 95% CI 0.28–0.72, p = 0.001) of consenting to receive these offers. 2773 candidates (87%) received a transplant. There was no significant association between HCV+ donor offer consent status and transplant rate after adjusting for candidate characteristics. Only 1 received a kidney from a HCV+ donor. Conclusions: Consent to receive HCV+ donor kidney offers was rare among pediatric kidney transplant candidates. Allocation changes that increase the proportion of pediatric‐prioritized kidneys that are HCV+ may decrease access to transplant for pediatric candidates.
- Open Access
- 22 August 2025
- Published by Elsevier in Kidney International
- Vol. 108 (6) , 1170-1178
Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection
- 22 August 2025
- Published by Elsevier in Kidney International
- Vol. 108 (6) , 1170-1178
Open AccessLow prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection